My Blog

Tag: Z21

  • Z21 Ventures announces investment in Basepair, a SaaS platform that democratizes access to, analysis of, and interpretation of genomic data

    Z21 Ventures announces investment in Basepair, a SaaS platform that democratizes access to, analysis of, and interpretation of genomic data

     

    Thanks to advances in next-generation sequencing (NGS) technology, genomic data is being generated on an unprecedented scale. Improvements in cloud computing resources have allowed the raw data to be processed and stored with ever-increasing efficiency. However, analyzing this data and gaining insights from it is still very challenging and limited to a select few due to technology restrictions. This results in reduced efficiency for R&D teams, longer times to market for assay manufacturers, and increased turnaround times in clinical settings.

     

    Basepair, a software-as-a-service (SaaS) platform, democratizes access to and the analysis and interpretation of genomic data. Basepair allows organizations to connect to and leverage the compute and storage resources in their own cloud account, allowing them to optimize their resources and realize greater business value. This allows them to remain connected to the other analytical capabilities offered by their cloud provider while benefiting from economies of scale by running everything through one account. This enables the end users with the appropriate domain expertise to run the same workflows in a controlled setting and use the inbuilt visualization tools and reports to make sense of the data.

     

    Z21 Ventures is pleased to announce our strategic investment in Basepair. This investment reflects our commitment to supporting innovative solutions and purposeful companies. Basepair aligns seamlessly with our vision, providing an innovative solution that makes bioinformatics easier, faster, and cost-effective.

     

    “z21 is more than just an investor; it’s a team of builders and operators. From the start, the investment process was efficient and well-managed. They have connected us with top-tier investors and talent in Silicon Valley. Behind the scenes, they actively help improve the business from the ground up. z21 should be the top choice for any founder.” – Amit U Sinha | Founder & CEO of Basepair

     

    We are thrilled about the investment and the upcoming collaboration with Basepair and the vibrant Z21 community. We eagerly anticipate the opportunity to work closely with the Basepair team, leveraging our collective expertise to propel them toward even greater heights in the genomics industry.

     

  • Announcing z21 Ventures investment in Meomind, the scalable alternative to psychotherapy

    Announcing z21 Ventures investment in Meomind, the scalable alternative to psychotherapy

     

    Outpatient psychotherapy is a $50Bn global market and $25Bn+ is spent on outpatient mental therapy every year in the US. Despite a widespread, growing, and acute need for therapy solutions, there isn’t a single one that is accessible in a timely way, affordable, and effective in driving clinical outcomes. Users need to wait for weeks to get in touch with a therapist who may or may not be the right fit for them. This significantly delays the process of seeking help and worsens the symptoms for many users. 

     

    z21 Ventures is pleased to announce our strategic investment in Meomind. By uniquely creating a vast library of pre-recorded therapy sessions, Meomind is on the path to providing on-demand access to high-quality relatable solutions to millions of users. With 70k+ members on the platform, 80% of members have reported feeling better in 2.5 weeks. This makes Meomind a great benefit that employers and health plans can offer to support the mental well-being of members.

     

    This partnership is a testament to our belief in the role of technology to make effective mental well-being solutions accessible to all. Meomind partners with world-class therapists to curate therapy sessions relatable to diverse scenarios.

     

    “The entire z21 team has been incredibly helpful in connecting us to a rich network of GTM experts, technologists, and investors. z21 has built a unique value proposition with the vast reach of its LPs who not only have deep expertise but are also very generous with their time and advice.” – Sushant Gupta, CEO, Meomind

     

    We look forward to working closely with Sushant and the Meomind team to disrupt the mental health landscape.